Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for $85 Per Share

Vertex Pharmaceuticals announced it will acquire Crinetics Pharmaceuticals in an all-cash transaction valued at $85 per share.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments